Dr. Michael Offin treats mesothelioma and lung cancers at MSK, including BRAF-mutated tumors, offering clinical trials and personalized, patient-focused care.
At Memorial Sloan Kettering Cancer Center, science, compassion, and hope come together to drive powerful advances in medical research and patient care. My desire to help patients and their families facing a cancer diagnosis is rooted in my own experience with cancer in my family. I know it can be such a difficult time.
Hi, I'm Dr. Michael Offin, and I'm a thoracic medical oncologist at MSK. As Co-Director of our collaborative MSK Mesothelioma Program, my work bridges groundbreaking laboratory research and transformative patient care to treat mesothelioma wherever it occurs.
I lead multiple clinical trials to advance the treatment of the most complex thoracic malignancies, turning scientific breakthroughs into life-changing patient care. Where you are treated first matters, and coming to MSK means you may have access to cutting-edge treatments not available anywhere else.
While I focus on the treatment of patients with mesothelioma, I also treat and study lung cancers. Specifically, I focus on developing effective treatments for lung cancers that harbor BRAF gene mutations, as well as conduct clinical trials and lab-based research.
By working closely with colleagues across multiple specialties, we create comprehensive care plans just for you. We support you through every stage of your journey, prioritizing your individual goals and your quality of life.
My team and I want to know what matters most to you, so we can align care around the life you want to get back to. Every member of your care team will know your story, and we share a deep commitment to achieving the best possible outcome for you.